IL91368A - OVIV NI Imaging of Oxygen Metabolites by Magnetic Resonance Proton Imaging - Google Patents

OVIV NI Imaging of Oxygen Metabolites by Magnetic Resonance Proton Imaging

Info

Publication number
IL91368A
IL91368A IL9136889A IL9136889A IL91368A IL 91368 A IL91368 A IL 91368A IL 9136889 A IL9136889 A IL 9136889A IL 9136889 A IL9136889 A IL 9136889A IL 91368 A IL91368 A IL 91368A
Authority
IL
Israel
Prior art keywords
agent
oxygen
imaging
compound
tissue
Prior art date
Application number
IL9136889A
Other languages
English (en)
Hebrew (he)
Other versions
IL91368A0 (en
Original Assignee
Gupte Pradeep
Arai Toshiyuki
Lasker Sigmund E
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gupte Pradeep, Arai Toshiyuki, Lasker Sigmund E filed Critical Gupte Pradeep
Publication of IL91368A0 publication Critical patent/IL91368A0/xx
Publication of IL91368A publication Critical patent/IL91368A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
    • G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
    • G01R33/5601—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/46—NMR spectroscopy
    • G01R33/465—NMR spectroscopy applied to biological material, e.g. in vitro testing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Physics & Mathematics (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Signal Processing (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL9136889A 1988-08-19 1989-08-20 OVIV NI Imaging of Oxygen Metabolites by Magnetic Resonance Proton Imaging IL91368A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/234,339 US4996041A (en) 1988-08-19 1988-08-19 Method for introducing oxygen-17 into tissue for imaging in a magnetic resonance imaging system

Publications (2)

Publication Number Publication Date
IL91368A0 IL91368A0 (en) 1990-04-29
IL91368A true IL91368A (en) 1995-05-26

Family

ID=22880951

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9136889A IL91368A (en) 1988-08-19 1989-08-20 OVIV NI Imaging of Oxygen Metabolites by Magnetic Resonance Proton Imaging

Country Status (9)

Country Link
US (1) US4996041A (ja)
EP (1) EP0386199B1 (ja)
JP (1) JP2655004B2 (ja)
AT (1) ATE121950T1 (ja)
AU (1) AU4066589A (ja)
CA (1) CA1336165C (ja)
DE (1) DE68922485T2 (ja)
IL (1) IL91368A (ja)
WO (1) WO1990001953A1 (ja)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0455836A4 (en) * 1989-11-24 1992-03-04 Toshiyuki Arai Nuclear magnetic resonance agent, detection thereof, and tomography using said agent
US5705187A (en) * 1989-12-22 1998-01-06 Imarx Pharmaceutical Corp. Compositions of lipids and stabilizing materials
US5305757A (en) * 1989-12-22 1994-04-26 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US6001335A (en) * 1989-12-22 1999-12-14 Imarx Pharmaceutical Corp. Contrasting agents for ultrasonic imaging and methods for preparing the same
US6146657A (en) * 1989-12-22 2000-11-14 Imarx Pharmaceutical Corp. Gas-filled lipid spheres for use in diagnostic and therapeutic applications
US6551576B1 (en) 1989-12-22 2003-04-22 Bristol-Myers Squibb Medical Imaging, Inc. Container with multi-phase composition for use in diagnostic and therapeutic applications
US5773024A (en) * 1989-12-22 1998-06-30 Imarx Pharmaceutical Corp. Container with multi-phase composition for use in diagnostic and therapeutic applications
US20020150539A1 (en) * 1989-12-22 2002-10-17 Unger Evan C. Ultrasound imaging and treatment
US5776429A (en) * 1989-12-22 1998-07-07 Imarx Pharmaceutical Corp. Method of preparing gas-filled microspheres using a lyophilized lipids
US5352435A (en) * 1989-12-22 1994-10-04 Unger Evan C Ionophore containing liposomes for ultrasound imaging
US6088613A (en) 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
US5585112A (en) * 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5469854A (en) * 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US5922304A (en) * 1989-12-22 1999-07-13 Imarx Pharmaceutical Corp. Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents
US5656211A (en) * 1989-12-22 1997-08-12 Imarx Pharmaceutical Corp. Apparatus and method for making gas-filled vesicles of optimal size
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
GB9005080D0 (en) * 1990-03-07 1990-05-02 Univ Nottingham Labelled markers
US5368840A (en) * 1990-04-10 1994-11-29 Imarx Pharmaceutical Corp. Natural polymers as contrast media for magnetic resonance imaging
ATE185489T1 (de) * 1990-04-10 1999-10-15 Imarx Pharmaceutical Corp Polymere als kontrastmittel bei magnetischer resonanz
US5874062A (en) * 1991-04-05 1999-02-23 Imarx Pharmaceutical Corp. Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents
US5205290A (en) 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
US5304325A (en) * 1991-11-13 1994-04-19 Hemagen/Pfc Emulsions containing alkyl- or alkylglycerophosphoryl choline surfactants and methods of use
EP0591544A4 (en) * 1992-03-26 1996-03-27 Toshiyuki Arai Reagent for nuclear magnetic resonance
US5339814A (en) * 1992-04-14 1994-08-23 Lasker Sigmund E Process for visualizing tissue metabolism using oxygen-17
WO1996003073A1 (en) * 1992-04-14 1996-02-08 Lasker Sigmund E Process for visualizing tissue metabolism using oxygen-17
JPH0625014A (ja) * 1992-07-13 1994-02-01 Toshiyuki Arai 核磁気共鳴剤
US5665382A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
US5650156A (en) * 1993-02-22 1997-07-22 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of nutriceuticals and compositions useful therefor
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US5362478A (en) * 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
US6280383B1 (en) * 1993-03-01 2001-08-28 Fonar Corporation Magnetic resonance imaging
US5433196A (en) * 1993-06-02 1995-07-18 The Board Of Trustees Of The University Of Illinois Oxygen-17 NMR spectroscopy and imaging in the human
US5716597A (en) * 1993-06-04 1998-02-10 Molecular Biosystems, Inc. Emulsions as contrast agents and method of use
IL106066A (en) * 1993-06-18 1997-04-15 British Tech Group Method of measuring the 17o content and distribution in a body
US7083572B2 (en) * 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
US6123919A (en) * 1994-04-08 2000-09-26 The Trustees Of Princeton University Magnetic resonance imaging using hyperpolarized noble gases
US5545396A (en) * 1994-04-08 1996-08-13 The Research Foundation Of State University Of New York Magnetic resonance imaging using hyperpolarized noble gases
US5736121A (en) * 1994-05-23 1998-04-07 Imarx Pharmaceutical Corp. Stabilized homogenous suspensions as computed tomography contrast agents
US6743779B1 (en) 1994-11-29 2004-06-01 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US5830430A (en) * 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
US6231834B1 (en) 1995-06-07 2001-05-15 Imarx Pharmaceutical Corp. Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same
US6139819A (en) * 1995-06-07 2000-10-31 Imarx Pharmaceutical Corp. Targeted contrast agents for diagnostic and therapeutic use
US6521211B1 (en) 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
US6033645A (en) * 1996-06-19 2000-03-07 Unger; Evan C. Methods for diagnostic imaging by regulating the administration rate of a contrast agent
WO1997040679A1 (en) 1996-05-01 1997-11-06 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US6414139B1 (en) 1996-09-03 2002-07-02 Imarx Therapeutics, Inc. Silicon amphiphilic compounds and the use thereof
US5846517A (en) * 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
JP4139440B2 (ja) * 1996-09-11 2008-08-27 イマアーレクス・フアーマシユーチカル・コーポレーシヨン 造影剤及び血管拡張薬を用いる画像診断のための改良された方法
US6143276A (en) * 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures
US6090800A (en) * 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6537246B1 (en) * 1997-06-18 2003-03-25 Imarx Therapeutics, Inc. Oxygen delivery agents and uses for the same
US20050019266A1 (en) * 1997-05-06 2005-01-27 Unger Evan C. Novel targeted compositions for diagnostic and therapeutic use
US6416740B1 (en) 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
US6548047B1 (en) 1997-09-15 2003-04-15 Bristol-Myers Squibb Medical Imaging, Inc. Thermal preactivation of gaseous precursor filled compositions
US6123923A (en) * 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
CA2336191C (en) * 1998-06-17 2008-12-16 Medi-Physics, Inc. Hyperpolarized gas transport devices and associated transport method
US6284222B1 (en) 1998-11-03 2001-09-04 Medi--Physics, Inc. Hyperpolarized helium-3 microbubble gas entrapment methods
EP1155339A1 (en) 1999-02-23 2001-11-21 Medi-Physics, Inc. Portable system for monitoring the polarization level of a hyperpolarized gas during transport
US6648130B1 (en) * 1999-08-11 2003-11-18 Medi-Physics, Inc. Hyperpolarized gas transport and storage devices and associated transport and storage methods using permanent magnets
WO2001067955A2 (en) * 2000-03-13 2001-09-20 Medi-Physics, Inc. Diagnostic procedures using direct injection of gaseous hyperpolarized 129xe and associated systems and products
US7407778B2 (en) * 2002-02-07 2008-08-05 Pettegrew Jay W Compounds, compositions and methods for treating neuropsychiatric disorders
US7700074B2 (en) * 2002-02-07 2010-04-20 Pettegrew Jay W Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism
US20060257842A1 (en) * 2003-05-29 2006-11-16 Pettegrew Jay W Cryopreservation media and molecules
DE602004022301D1 (de) * 2003-05-29 2009-09-10 Jay W Pettegrew Glycerophosphocholin und derivate davon zur medizinischen abbildung von neuropsychiatrischen erkrankungen
EP1713513B1 (en) * 2004-01-16 2014-06-04 Carnegie Mellon University Cellular labeling for nuclear magnetic resonance techniques
EP1865993A2 (en) * 2005-04-05 2007-12-19 Biopure Corporation Oxygenated polymerized hemoglobin solutions and their uses for tissue visualization
US7410634B2 (en) * 2005-10-17 2008-08-12 Rockland Technimed Ltd. Tissue metabolic stress monitoring
EP2012832A2 (en) * 2006-04-14 2009-01-14 Celsense, Inc. Methods for assessing cell labeling
EP2010646A2 (en) * 2006-04-14 2009-01-07 Carnegie Mellon University Cellular labeling and quantification for nuclear magnetic resonance techniques
US8227610B2 (en) * 2007-07-10 2012-07-24 Carnegie Mellon University Compositions and methods for producing cellular labels for nuclear magnetic resonance techniques
JP5751708B2 (ja) * 2008-05-02 2015-07-22 セルセンス， インコーポレイテッド 核磁気共鳴技法および他の用途のためのエマルジョンを生成するための組成物ならびに方法
WO2013043236A1 (en) * 2011-09-22 2013-03-28 Rockland Technimed, Ltd. Compositions and methods useful for realtime in situ physiological molecular imaging of oxygen metabolism

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4586511A (en) * 1983-03-04 1986-05-06 Children's Hospital Medical Center Methods and compositions for detecting and imaging a gas in an animal by nuclear magnetic resonance
US4775522A (en) * 1983-03-04 1988-10-04 Children's Hospital Research Foundation, A Division Of Children's Hospital Medical Center NMR compositions for indirectly detecting a dissolved gas in an animal
EP0231091B1 (en) * 1986-01-24 1993-03-31 Children's Hospital Medical Center Stable emulsions of highly fluorinated organic compound

Also Published As

Publication number Publication date
CA1336165C (en) 1995-07-04
US4996041A (en) 1991-02-26
IL91368A0 (en) 1990-04-29
EP0386199B1 (en) 1995-05-03
DE68922485D1 (de) 1995-06-08
EP0386199A1 (en) 1990-09-12
AU4066589A (en) 1990-03-23
JPH03500896A (ja) 1991-02-28
ATE121950T1 (de) 1995-05-15
JP2655004B2 (ja) 1997-09-17
EP0386199A4 (en) 1990-11-07
DE68922485T2 (de) 1996-01-18
WO1990001953A1 (en) 1990-03-08

Similar Documents

Publication Publication Date Title
US4996041A (en) Method for introducing oxygen-17 into tissue for imaging in a magnetic resonance imaging system
Nöth et al. 19F‐MRI in vivo determination of the partial oxygen pressure in perfluorocarbon‐loaded alginate capsules implanted into the peritoneal cavity and different tissues
Möller et al. MRI of the lungs using hyperpolarized noble gases
Adam et al. Gd‐DTPA‐cascade‐polymer: potential blood pool contrast agent for MR imaging
US4838274A (en) Perfluoro-crown ethers in fluorine magnetic resonance imaging
US5248498A (en) Fullerene compositions for magnetic resonance spectroscopy and imaging
KR100834255B1 (ko) 핵 스핀 편극화 ｍｒ 영상화제를 사용한 샘플의 자기 공명연구 방법
Livramento et al. First in vivo MRI assessment of a self‐assembled metallostar compound endowed with a remarkable high field relaxivity
Majumdar et al. Pharmacokinetics of superparamagnetic iron-oxide MR contrast agents in the rat
US6051208A (en) In vivo magnetic resonance vascular imaging using laser-polarized gas microbubbles
AU2001286093A1 (en) Method of magnetic resonance investigation of a sample using a nuclear spin polarised MR imaging agent
Goo et al. Time‐resolved three‐dimensional contrast‐enhanced magnetic resonance angiography in patients who have undergone a Fontan operation or bidirectional cavopulmonary connection: initial experience
KR960010800B1 (ko) 자기공명 영상방법
Li et al. Three‐dimensional low dose gadolinium‐enhanced peripheral MR venography
Berthezene et al. Differentiation of alveolitis and pulmonary fibrosis with a macromolecular MR imaging contrast agent.
Attenberger et al. Comparative evaluation of lesion enhancement using 1 M gadobutrol vs. 2 conventional gadolinium chelates, all at a dose of 0.1 mmol/kg, in a rat brain tumor model at 3 T
Baklanov et al. Novel double contrast MRI technique for intramyocardial detection of percutaneously transplanted autologous cells
Murugesan et al. Fluorine electron double resonance imaging for 19F MRI in low magnetic fields
MEYER et al. Fluorinated blood substitute retention in the rat measured by fluorine-19 magnetic resonance imaging
Fries et al. Brain tumor enhancement in magnetic resonance imaging at 3 tesla: intraindividual comparison of two high relaxivity macromolecular contrast media with a standard extracellular gd-chelate in a rat brain tumor model
US20050053551A1 (en) Use of a combination of gadolinium-based contrast media and iodinated contrast media as a contrast agent for X-ray based medical imaging procedures
Thomas et al. Quantitative pO2 imaging in vivo with perfluorocarbon F-19 NMR: tracking oxygen from the airway through the blood to organ tissues
Roberts et al. Dynamic observation of pulmonary perfusion using continuous arterial spin‐labeling in a pig model
Chawla et al. Hyperpolarized 3He microspheres as a novel vascular signal source for MRI
JPH107592A (ja) 磁気共鳴画像診断装置による組織内酸素−１７の 測定方法

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired